This article is more than 5 years old. Information may no longer be current.

Mitomycin offers better long-term IOP control in triple procedure

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DETROIT — Intraocular pressure control and visual field preservation were better after glaucoma triple procedure with adjunctive mitomycin than without, according to a study here.

Researchers at the Kresge Eye Institute reviewed the records of 183 eyes with primary open-angle glaucoma (POAG) that had undergone trabeculectomy, cataract removal and IOL implantation either with adjunctive subconjunctival mitomycin-C or without. Comparisons were made between those that had received MMC (124 eyes) and those that had not (59 eyes).

At the 36-month follow-up point, both groups attained significant decreases in mean IOP and the mean number of anti-glaucoma medications. However, the MMC group had significantly lower mean IOP than the control group at all postop visits (P < .05). The MMC group also tended to have less medical dependency postop than the control group.

No significant difference in best corrected visual acuity was found between the two groups. There was a significant worsening of visual fields as measured by a global index on the Humphrey perimeter in the control group, but no significant change in the MMC group.

The study is published in the September issue of Ophthalmology.